Nexalin Technology, Inc. — fact timeline

Nexalin Technology, Inc.: Adopted Second Amended and Restated Bylaws with changes to stockholder nomination procedures, quorum, written consent, board provisions, indemnification, forum selection, and other updates (effective 2026-06-16).

“On June 16, 2026, the Board of Directors (the “ Board ”) of Nexalin Technology, Inc. (the “ Company ”) adopted the Company’s Second Amended and Restated Bylaws (as so amended and restated, the “ Second Amended and Restated Bylaws ”), which became effective immediately upon adoption.”

Nexalin Technology, Inc. entered into Collaboration Agreement with GreenLight Ventures LLC valued at 10,000 per month (effective 2026-05-14).

“On May 14, 2026, the Company entered into a Collaboration Agreement (the “Collaboration Agreement”) with GLV to support the development, compliance and commercialization of the Company’s cranial electrotherapy stimulation technologies and related products using certain licensed software associated with GLV’s digital technology platforms.”

Nexalin Technology, Inc. entered into Stock Purchase Agreement with GreenLight Ventures LLC valued at 1,300,000 (effective 2026-05-14).

“On May 14, 2026, Nexalin Technology, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with GreenLight Ventures LLC, a North Carolina limited liability company (“GLV”).”

Nexalin Technology, Inc. entered into Scope of Work with Lindus Health Limited valued at approximately $944,820 (effective 2026-04-17).

“On April 17, 2026, Nexalin Technology, Inc. (the “Company”) entered into a Scope of Work (the “SOW”) with Lindus Health Limited (“Lindus Health”), a clinical research organization based in the United Kingdom.”

Nexalin Technology, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 21, 2026, Nexalin Technology, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.001per share (“Common Stock”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid R”

Nexalin Technology, Inc. engaged CBIZ CPAs P.C. as its auditor.

“Also on April 16, 2025, the Company, with the approval of the Audit Committee of the Company’s Board of Directors, engaged CBIZ CPAs P.C. as the Company’s independent registered public accounting firm.”

Marcum LLP resigned as auditor of Nexalin Technology, Inc..

“On April 16, 2025, Marcum informed Nexalin Technology, Inc. (the “Company”) that Marcum resigned as the Company’s independent registered public accounting firm.”

Carolyn Shelton was appointed as Senior Vice President Quality, Regulatory and Clinical Affairs at Nexalin Technology, Inc..

“On September 16, 2024, Nexalin Technology, Inc. (“Nexalin”) appointed Carolyn Shelton as Senior Vice President Quality, Regulatory and Clinical Affairs, effective as of September 16, 2024.”

Michael Nketiah resigned as Senior Vice President of Clinical, Quality, & Regulatory Affairs at Nexalin Technology, Inc..

“On July 29, 2024, Michael Nketiah submitted his resignation as the Senior Vice President of Clinical, Quality, & Regulatory Affairs of Nexalin Technology Inc. (the "Company").”

Nexalin Technology, Inc. shareholders approved Approval of an amendment to the Company’s Certificate of Incorporation, as amended to date (the “Reverse Stock Split Amendment”), to effect a reverse stock split of the Company’s common stock and give the Company’s Board of Directors the authority to determine whether filing such Reverse Stock Split at the 2024-03-07 meeting.

“Proposal One: Approval of an amendment to the Company’s Certificate of Incorporation, as amended to date (the “ Reverse Stock Split Amendment ”), to effect a reverse stock split of the Company’s common stock and give the Company’s Board of Directors the authority to determine whether filing such Reverse Stock Split Amendment is necessary and, if so, the ratio of such split: For Against Abstained 4,304,448 259,736 23,064”

Nexalin Technology, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“November 7, 2023, the Company submitted a letter to NASDAQ requesting a second 180-day period in order to regain compliance with NASDAQ Rule 5550(a)(2). The Company stated in that letter that it believed it would be able to cure the deficiency and increase its stock price to above $1.00 per share pursuant to a plan set forth in such letter. On November 7, 2023, the Company received written notice from the Nasdaq Listing Qualifications Department (the “Staff”) that the Company was not eligible for an additional 180 calendar day compliance period because the Company no longer complied with Nasda”

Marilyn Elson resigned as Chief Financial Officer at Nexalin Technology, Inc..

“On September 21, 2023, Marilyn Elson submitted her resignation as the Chief Financial Officer of Nexalin Technology Inc. (the “Company”).”

Nexalin Technology, Inc. entered into Joint Venture Agreement with Wider Come Limited (effective 2023-05-31).

“On May 31, 2023, Nexalin Technology, Inc. (the “Company”) formalized an agreement related to the formation of a joint venture”

Nexalin Technology, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“May 10, 2023, Nexalin Technology, Inc. (the “Company”) received written notice (the “Notice”) from the Nasdaq Stock Market (“Nasdaq”) that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Market, pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). The Notice has no immediate effect on the listing of the Company’s common stock on The Nasdaq Global Market. Pursuant to Nasdaq Listing R”